SCHEMBL5069607

SCHEMBL5069607

CC(C)(C)OC(=O)N1CCC(Cn2nc(C(F)(F)F)cc2C(=O)O)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
STS P08842 2/20 0.46
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
SFRP1 Q8N474 2/20 0.43
TGFBR1 P36897 3/20 0.42
EPHX2 P34913 1/20 0.42
GPR119 Q8TDV5 4/20 0.41
RORC P51449 1/20 0.41
FAAH O00519 1/20 0.41
PIK3CD O00329 1/20 0.41
PIK3R2 O00459 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
PIK3R5 Q8WYR1 1/20 0.41
PIK3R3 Q92569 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5066894 0.81 STS (0.46) STSKDM4ESFRP1GPR119
SCHEMBL24758363 0.80 GAA (0.44) KDM4E
SCHEMBL24758385 0.79 GAA (0.43)
SCHEMBL5070468 0.79 CARM1 (0.49) EPHX2
SCHEMBL4564075 0.79 GPR119 (0.49) KDM4EPKMTGFBR1GPR119RORC
SCHEMBL5069612 0.77 SRC (0.42) STSSFRP1GPR119PIK3CDPIK3R2
SCHEMBL5069610 0.77 SRC (0.42) STSSFRP1GPR119PIK3CDPIK3R2
SCHEMBL24758364 0.77 SLC2A1 (0.44) KDM4E
SCHEMBL24758362 0.76 CRHR1 (0.39) KDM4E
SCHEMBL3761678 0.75 GRN (0.58) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-8338437-B2 Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy METHYLGENE INC. (CA) 2012-12-25 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed
US-20080280925-A1 Amines as Small Molecule Inhibitors METHYLGENE INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280925-A1 Amines as Small Molecule Inhibitors CARM1, PRMT1, PRMT3 STS 3667/4885KDM4E 369/4885PKM 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.